ProMIS Neurosciences, Inc. Stock Toronto S.E.
Equities
PMN
CA74346M4065
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 58.09M 42.58M |
---|---|---|---|---|---|
Net income 2024 * | -23M -16.86M | Net income 2025 * | -34M -24.92M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.28
x | P/E ratio 2025 * |
-3.25
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.67% |
Managers | Title | Age | Since |
---|---|---|---|
Neil Warma
CEO | Chief Executive Officer | 61 | 21-05-12 |
Neil Cashman
FOU | Founder | 72 | 04-01-22 |
Eugene Williams
CHM | Chairman | 64 | 15-06-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Wyman
BRD | Director/Board Member | 86 | 14-03-07 |
Neil Cashman
FOU | Founder | 72 | 04-01-22 |
Neil Warma
CEO | Chief Executive Officer | 61 | 21-05-12 |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |